Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · Metabolic

Hypothalamic and syndromic obesity — indication assessment

Obesity arising from structural hypothalamic injury or a defined genetic syndrome affecting the melanocortin pathway or energy homeostasis.

Document identifier
CEI-IN-10
Series
Indication assessment
Version
1.3
Published
11 Apr 2026
Last reviewed
11 Apr 2026
Next review
11 Apr 2028
Identifier
10.71829/cei.ind.10
Certainty
Not rated
Cycle
2026 Q2
ICD-11
5B81.Y
Category
Metabolic

§1Assessment

§1.1Definition

Obesity arising from structural hypothalamic injury or a defined genetic syndrome affecting the melanocortin pathway or energy homeostasis.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

  1. Change in BMI
  2. Change in hyperphagia questionnaire score
  3. Change in resting energy expenditure

§1.3State of the evidence

Distribution of certainty ratingsShare of assessed outcomes at each certainty level.1compounds
HighModerateLowVery low
Figure 1. Certainty ratings across the 0 compounds the Institute assesses for this indication. A high rating for one compound says nothing about another.

No compound in the Institute's set has an assessed outcome in this indication. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.

Compound Evidence Institute · CEI-IN-10 · https://compoundevidence.com/indications/hypothalamic-obesity/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.